SNMMI Procedure Standard for Scintigraphy for Differentiated Thyroid Cancer

Twyla B. Bartel (Chair), DO, FACNM1, Samuel Magerefteh2, Anca M. Avram, FACNM3, Helena R. Balon4, Lorraine E. De Blanche, FACNM5, Simin Dadparvar, FACR, FACNM6, Mickaila Johnston, CDR, MC, USN, FACNM7, and Shari Moreau, CNMT8

1Global Advanced Imaging, PLLC, Little Rock, Arkansas; 2Prohealth Advanced Imaging, Beverly Hills, California; 3University of Michigan Medical Center, Ann Arbor, Michigan; 4Beaumont Hospital, Royal Oak, Michigan; 5Virginia Dallas Department of Nuclear Medicine, Dallas, Texas; 6Temple University, Philadelphia, Pennsylvania; 7Naval Medical Center, San Diego, California; and 8Washington Hospital, Washington, D.C

PREAMBLE

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and professional organization founded in 1954 to promote the science, technology, and practical application of nuclear medicine. Its 18,000 members are physicians, technologists, and scientists specializing in the research and practice of nuclear medicine. In addition to publishing journals, newsletters, and books, the SNMMI also sponsors international meetings and workshops designed to increase the competencies of nuclear medicine practitioners and to promote new advances in the science of nuclear medicine.

The SNMMI will periodically define new procedural recommendations for nuclear medicine practice to help advance the science of nuclear medicine and to improve the quality of service to patients. Existing practice guidelines will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner, if indicated.

Each procedural recommendation, representing a policy statement by the SNMMI, has undergone a thorough consensus process in which it has been subjected to extensive review. The SNMMI recognizes that the safe and effective use of diagnostic nuclear medicine imaging requires specific training, skills, and techniques, as described in each document.

These procedural recommendations are an educational tool designed to assist practitioners in providing appropriate care for patients. They are not inflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care. For these reasons and those set forth below, the SNMMI cautions against the use of these procedural recommendations in litigation in which the clinical decisions of a practitioner are called into question.

The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by the physician in light of all the circumstances presented. Thus, an approach that differs from the procedural recommendations, standing alone, does not necessarily imply that the approach was below the standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set forth in the procedural recommendations when, in the reasonable judgment of the practitioner, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology subsequent to publication of the procedural recommendations.

The variety and complexity of human conditions make it impossible to always reach the most appropriate diagnosis or to predict with certainty a particular response to treatment. Therefore, it should be recognized that adherence to these procedural recommendations will not ensure an accurate diagnosis or a successful outcome. All that should be expected is that the practitioner will follow a reasonable course of action based on current knowledge, available resources, and the needs of the patient to deliver effective and safe medical care. The sole purpose of these procedural recommendations is to assist practitioners in achieving this objective.

I. INTRODUCTION

Surgical histopathology, diagnostic and posttherapy radioiodine (RAI) scintigraphy, and postoperative thyroglobulin (Tg) provide information contributing to differentiated thyroid cancer (DTC) staging, risk stratification, and clinical management. The purpose of this document is to provide the procedure standard on the RAI scintigraphy aspect of DTC management. The addition of SPECT/CT to planar RAI imaging has been shown to reduce equivocal findings and improve staging in these patients.
II. GOALS
The goal of this procedure standard is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of scintigraphy for DTC.

III. DEFINITIONS
Radioactive iodine (RAI) is taken up by functioning benign or malignant thyroid tissue based on sodium-iodide symporter (NIS) expression. RAI scintigraphy with $^{131}$I-NaI or $^{123}$I-NaI can be performed after total thyroidectomy and before RAI ablation, after therapeutic $^{131}$I-NaI administration, or as surveillance for identification and localization of regional and distant DTC metastases. The typical images acquired are planar anterior and posterior whole-body along with spot views of the neck and chest and with additional SPECT/CT as clinically indicated.

Radiotheranostics for thyroid cancer integrates diagnostic imaging and therapeutic radionuclides, with $^{131}$I-NaI being the classic example of a radiotheranostic agent for this purpose. This document focuses on the imaging aspect of this equation.

Thyroglobulin (Tg) is a dimeric protein produced by the follicular cells of the thyroid gland, can be elevated in residual thyroid tissue, and is used as a DTC tumor marker after total thyroidectomy and postoperative thyroid remnant ablation.

Tg antibody is a class G immunoglobulin and can also be elevated in recurrent thyroid cancer.

$^{18}$F-FDG PET may be helpful for detecting recurrent thyroid cancer in cases of a rising serum Tg and negative radioiodine imaging.

IV. COMMON CLINICAL INDICATIONS
The common clinical indication for using thyroid scintigraphy as outlined here is for the detection of the presence of and localization of any functioning residual, recurrent, or metastatic DTC. This includes patients shortly after thyroidectomy and before or after $^{131}$I-NaI treatment of iodine-avid tissue as well as for any surveillance.

V. QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL
A. Physician
Scintigraphic imaging for DTC should be performed under the supervision of a physician specialized in nuclear medicine and certified by the appropriate board.

B. Technologist
Scintigraphic imaging for DTC should be performed by a qualified registered or certified nuclear medicine technologist. Refer to the Responsibility and Guidelines for the Nuclear Medicine Technologist for further details.

C. Medical Physicist
The medical physicist should be involved in protocol/image acquisition and processing as necessary including as recommended by the manufacturer.

VI. PROCEDURE
Also see the SNMMI Procedure Standard for General Imaging.

A. Study Requisition and Appropriateness
The requisition should include all clinical information about the patient necessary for correct coding of the study. The requisition should also indicate the ability of the patient to cooperate, if there is need for mild sedation or analgesia, and whether the patient needs to be accompanied by a guardian. The examination request should be reviewed by the nuclear medicine staff and as needed by the nuclear medicine physician for appropriateness. The patient should also be contacted by the nuclear medicine department for any prescan instructions (i.e., low iodine diet), to give general information regarding the requested nuclear medicine procedure (i.e., fasting requirements, laboratory to assess pregnancy status, anticipate length of study), and to establish a doctor/patient relationship.

B. Patient Preparation
Avoid Materials That Can Interfere with Uptake of $^{131}$I-NaI or $^{123}$I-NaI. The concentration of radioiodine in functioning benign or malignant thyroid tissue is affected by many interfering factors, and imaging should be delayed for a period long enough to eliminate their competing effects.

- Medications/drugs that may interfere with RAI uptake (RAIU): Common interfering medications with recommended withdrawal times before RAI administration are listed in Table 1.

- Iodine-containing food and supplements: Optimal preparation for RAI scintigraphy includes a 1- to 2-wk low-iodine diet with the goal of minimizing competitive inhibition by stable alimentary iodide ($^{127}$I). This is to ensure proper uptake of the radiopharmaceutical by functioning thyroid tissue and to increase imaging sensitivity. Kelp, certain multivitamins, and products made with red food dye number 3 are examples of common iodine-containing ingestible products. A simple practical method of confirming that a low-iodine diet has been followed is by performing a random spot urine iodine measurement (U.S. adult population reference range: 26–705 mcg/L). A level < 100 mcg/L is considered adequate preparation, and < 50 mcg/L is considered optimal preparation for RAI scintigraphy for DTC. A morning urine specimen provides the most adequate evaluation of recent dietary iodine intake.

- Intravenous contrast: Water-soluble iodinated intravenous contrast must be avoided for 3–4 wk before RAI administration.

Optimize Thyroid-Stimulating Hormone (TSH) Levels. Appropriately elevated TSH levels at the time of postoperative RAI scintigraphic evaluation and therapeutic $^{131}$I-NaI administration are required for increasing the NIS expression in metastatic lesions (and residual thyroid tissue) resulting from symporter ($^{131}$I-NaI) expression.

SNMMI Procedure Standard • Bartel et al. 203
in increased diagnostic sensitivity of RAI scintigraphy and increased radiation-absorbed dose to target lesions. TSH levels ≥ 30 mIU/L (measured 1–3 d before RAI administration) are considered adequate and can be achieved by either a thyroid hormone withdrawal (THW) (hypothyroid status) or a recombinant human TSH (rhTSH) stimulation during levothyroxine (L-T4) therapy (euthyroid status).

- **THW**: This consists of L-T4 deprivation for 3 to 4 wk or triiodothyronine (T3) treatment for 4 wk with subsequent T3 discontinuation for 2 wk before RAI scintigraphy.

- **rhTSH stimulation**: This consists of administration of rhTSH given as 2 intramuscular injections of 0.9 mg on each of 2 consecutive days with RAI or 18F-FDG given the next day. rhTSH may be required if the patient cannot be prepared by near-total thyroidectomy, in patients with significant comorbidities in whom prolonged hypothyroidism would represent a risk or cannot be tolerated, in patients with pituitary insufficiency, or in those with isolated THD deficiency.

- **Side effects**: The patient should be informed of the potential side effects of rhTSH injection and of hypothyroidism from THW. In order to avoid severely symptomatic, prolonged hypothyroidism, patients may be maintained on T3 until 10–14 d before administration of RAI.

- **Considerations for the TSH optimization preparation**: The choice of preparation method (THW vs. rhTSH) is a very complex issue and needs to be individualized for each patient. Important considerations include:
  1. There is agreement that for normal thyroid tissue (i.e., thyroid remnant), rhTSH and THW stimulation are equivalent, because normal thyroid tissue has constitutive high expression of highly functional Na-I symporters and does not require prolonged TSH stimulation for adequate RAIU and retention.
  2. However, metastatic thyroid cancer has lesser density and poorer functionality of Na-I symporters, and therefore, TSH elevation over time (area under the curve of TSH stimulation) is important to promote increased RAIU and retention in tumors. Across 2 clinical studies, rhTSH-stimulated scans failed to detect remnant or cancer localized to the thyroid bed in 17% of patients and metastatic disease in 29% in whom it was detected by a scan after L-T4 withdrawal (Thyrogen package insert).
  3. The level of Tg elevation after rhTSH stimulation is 3–5 times less than that obtained after THW, which may result in suboptimal evaluation of postoperative disease burden.

### Additional Laboratory Values.
- **TSH and Tg**: If the patient has undergone THW, TSH and Tg values should be obtained 1–3 d before a diagnostic RAI dose. Knowledge of TSH-stimulated Tg levels is very useful, especially in interpreting negative scintigraphic findings. Typically, a Tg level of < 1.0 ng/mL indicates remission, whereas a level > 10 indicates persistent disease. For the rhTSH protocol, Tg should be evaluated at baseline (before rhTSH administration) and at 3 d after the second dose of rhTSH.
- **Anti-Tg antibody**: Anti-Tg antibody can falsly elevate or lower Tg levels invalidating the serum Tg measurement. Therefore, Tg antibody assays must also be obtained in tandem with Tg testing.

### Information Pertinent to Performing the Procedure. A summary of information pertinent to performing the procedure is provided in Table 2.

### C. Precautions/Contraindications
#### Pregnancy/Breastfeeding
- **Urine pregnancy test**: On the day of scheduled 131I-NaI administration for females 12–55 y old, unless there is clear documentation that pregnancy cannot be possible (e.g., previous bilateral oophorectomy), a urine or serum pregnancy test is recommended in addition to clinical history to verify absence of pregnancy.
- **Pregnancy after RAI administration**: Patients should be advised to avoid pregnancy for at least 6 mo after 131I-NaI administration.
- **Breastfeeding before RAI administration**: To allow for breast tissue involution and minimize 131I-NaI uptake and radiation-absorbed dose to the maternal breast as well as to prevent the nursing child from ingesting radioactive breast milk, breastfeeding should be discontinued for at least 6 wk (but preferably for 3–6 mo) before RAI administration.
- **Breastfeeding after RAI administration**: After 131I-NaI administration, breastfeeding must be discontinued. It can be resumed after the birth of another child. If 123I-NaI is given, breastfeeding can be resumed 72 h later. For 18F-FDG, breastfeeding should be discontinued for 4 h.

### Representative Drugs/Supplements That Interfere With Radioiodine (in Alphabetical Order)

<table>
<thead>
<tr>
<th>Name</th>
<th>Withdrawal time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amiodarone</td>
<td>3–6 mo</td>
</tr>
<tr>
<td>Antitussives</td>
<td>2–4 wk</td>
</tr>
<tr>
<td>Bromides</td>
<td>1 wk</td>
</tr>
<tr>
<td>L-T4 ointments</td>
<td>2–4 wk</td>
</tr>
<tr>
<td>Levotyroxine (T4)</td>
<td>4–6 wk</td>
</tr>
<tr>
<td>Lugol’s solution</td>
<td>2–3 wk</td>
</tr>
<tr>
<td>Mineral/vitamin supplements</td>
<td>2–4 wk</td>
</tr>
<tr>
<td>Nitrates</td>
<td>1 wk</td>
</tr>
<tr>
<td>Perchlorate</td>
<td>1 wk</td>
</tr>
<tr>
<td>Potassium iodide</td>
<td>2–3 wk</td>
</tr>
<tr>
<td>Salicylates (large doses)</td>
<td>1 wk</td>
</tr>
<tr>
<td>Steroids</td>
<td>Variable</td>
</tr>
<tr>
<td>Sulfonamides</td>
<td>1 wk</td>
</tr>
<tr>
<td>Triiodothyronine (T3)</td>
<td>2–3 wk</td>
</tr>
</tbody>
</table>
D. Radiopharmaceuticals and Dosage

The following are recommended diagnostic imaging dosages.

**Oral ¹³¹I-NaI.** For diagnostic imaging, 37–148 MBq (1–4 mCi) are given, with many preferring a range of 37–74 MBq (1–2 mCi) because of data suggesting that stunning (decreased uptake of the therapy dose of ¹³¹I-NaI by residual functioning thyroid tissue or tumor due to cell death or dysfunction caused by the activity administered for diagnostic imaging) is less likely at the lower administered activity. However, stunning may not influence the outcome of treatment. The method of TSH stimulation also needs to be considered in deciding the activity used for diagnostic ¹³¹I-NaI scintigraphy, usually as: 37–74 MBq (1–2 mCi) if the patient is hypothyroid and 111–148 MBq (3–4 mCi) if a rhTSH-stimulation protocol was followed. There is no consensus practice parameter for weight-based administration for children.

**Oral ¹²³I-NaI.** The typical administered dosage for diagnostic imaging is between 74 and 148 MBq (2–4 mCi). As with ¹³¹I-NaI, the ¹²³I-NaI administered should take into consideration the method of TSH stimulation, typically the lower end of the activity range if the patient is hypothyroid and upper if rhTSH stimulation was followed. There is no consensus practice parameter for weight-based administration for children.

**¹⁸F-FDG.** The typical administered dosage for oncology imaging is between 74 and 148 MBq (2–4 mCi). ¹⁸F-FDG may be used to identify tumors that are not detected with RAI. These are usually less well-differentiated tumors (¹⁸F-FDG–positive, radioiodine-negative) and are less likely to respond to ¹³¹I-NaI treatment. These tumors may be more aggressive; may have a less favorable prognosis; and may be amenable to surgical resection, external radiation, or embolization. Imaging with ¹⁸F-FDG is more sensitive when the serum TSH is elevated (THW or rhTSH stimulation).

E. Imaging

**Clinical Settings for Imaging.**

- **Post-thyroidectomy, pre-RAI ablation imaging:** Nuclear medicine physicians are divided as to the need for preablation imaging. The American Thyroid Association (ATA) guidelines recommend that a postoperative diagnostic RAI scan may be useful when the extent of the thyroid remnant or residual disease cannot be accurately ascertained from the surgical report or neck ultrasonography and when the results may alter the decision to treat or the activity of RAI that is to be administered. Despite differing practices regarding preablation diagnostic RAI imaging, one must recognize that the following may be uncovered or useful:
  1. Diagnostic RAI scintigraphy may reveal unexpected iodine-avid metastatic disease in 22%–35% cases and change management in approximately 30%–50% cases as compared with an imaging strategy that does not include diagnostic scintigraphy.
  2. Approximately 1% of the time, the thyroidectomy is truly total, and if there are no remnants or other foci of iodine-avid tissue on the scan, then giving radioiodine would not be indicated. However, in high-risk patients, treatment of occult metastases may be warranted.
  3. The scan is useful in helping to determine the ¹³¹I-NaI dosage for ablation or therapy. Larger therapeutic RAI activities are usually given for treatment if regional or distant metastases are detected on the preablation scan.
  4. Distant metastases in the brain or spinal cord may require preradiation corticosteroids to avoid complications caused by radiation-induced swelling.
  5. Identification and localization of abnormal foci on planar imaging may be enhanced by concomitant SPECT/CT imaging.

- **Post-thyroidectomy, post-RAI ablation imaging**
- **Post-thyroidectomy/post-RAI ablation imaging for surveillance:** Scintigraphy for surveillance is tailored per the risk stratification of the patient and is an ongoing...
dynamic process. In general, a low-risk patient may not require surveillance, but it is recommended for intermediate to high risk for recurrent DTC and for those with rising Tg levels and a negative cervical ultrasound.

**Instrumentation.**
- $^{131}$I-NaI: A large field-of-view dual-head $\gamma$-camera fitted with a high-energy parallel-hole collimator is used. A 15%–20% window is centered on the 364-keV photopeak.
- $^{123}$I-NaI: A low- or medium-energy collimator is used depending on the manufacturer’s specifications. A 15%–20% window is centered on the 159-keV photopeak.
- $^{18}$F-FDG: Follow a usual PET/CT oncology protocol.

**Patient Maneuvers.**
- Clearance of confounding physiologic activity: The patient should drink a large glass of water or chew and swallow crackers before each set of images to clear physiologic pharyngeal or esophageal activity.
- Imaging position: The patient should lie supine on an imaging table with the neck slightly extended. Include the chin and arms in the field of view.

**Timing.**
- $^{131}$I-NaI: Preablation and surveillance images are obtained between 24 and 72 h after RAI administration (24-h images may not have clearly defined activity, thus the patient may need to be brought back at 48–72 h to improve lesion detection repeat imaging to allow an improved target to background ratio). Post-RAI ablation images can be obtained 2–7 d after treatment.
- $^{123}$I-NaI: Preablation or surveillance images are obtained 6–24 h after administration of this radiopharmaceutical. Some prefer $^{123}$I-NaI as images are of higher quality than with $^{131}$I-NaI and stunning may be prevented, but cost or availability may be a limiting factor for $^{123}$I.
- $^{18}$F-FDG: Images are acquired approximately 60 min after injection of the radiopharmaceutical. When there is suspicion that the $^{131}$I-NaI scan will be negative or have low sensitivity, an $^{18}$F-FDG scan should be performed while TSH levels are elevated (THW or rhTSH protocol). Koranda et al. demonstrated that when the TSH level is stimulated to $> 30$ mU/L in patients with radioiodine-negative scans, a large number of cases were true-positive on $^{18}$F-FDG PET/CT for detecting recurrent/metastatic disease.

**Acquisition.**
- Whole-body scan: Anterior and posterior planar parallel-hole collimator $\gamma$-camera images from the top of the skull through the femurs are obtained with a scan speed of 8 cm/min to 10 cm/min with a $256 \times 256$ matrix. Longer acquisition times may be helpful for images obtained more than 3 d after administration of $^{131}$I-NaI. A $256 \times 1,024$ matrix may be used for $^{123}$I-NaI.

**Spot images:** Static images should be acquired for 20 min using a $256 \times 256$ matrix per view to include the nasopharynx, thyroid bed, or chest. These images may improve lesion detection.

**Pinhole images:** Further pinhole images of selected areas may be acquired as deemed necessary for single photon emitters. These images may improve lesion detection.

**Markers:** In the neck, radioactive anatomic markers may be helpful in differentiating between normal residual thyroid tissue, salivary gland uptake, residual thyroid cancer, and lymph node metastasis.

**SPECT/CT:** This is helpful for more accurate anatomic lesion localization and especially for identifying lymph nodes in the neck, differentiating mediastinal versus lung uptake, or evaluating for bone metastases. SPECT/CT is preferred over planar imaging to anatomically localize concerning areas of uptake seen on the whole-body RAI scan. One study has shown that diagnostic RAI scans with SPECT/CT performed after total thyroidectomy detected regional metastases in 35% of patients and distant metastases in 8%. This resulted in a change in clinical management in approximately 30% of patients as compared with a management strategy based on surgical pathology alone. If available, SPECT/CT imaging should be performed with an axial field of view extending from the skull base to the diaphragm. In addition, all foci of abnormal activity seen on planar images outside the neck and chest that do not conform to a physiologic distribution should be further evaluated with SPECT/CT. The patient is imaged with arms down and without immobilizers. Imaging is performed on a hybrid dual-head $\gamma$-camera with an inline CT scanner. The following are recommended CT image parameters: 130 kVp, 80 mAs, 3 mm collimation, 0.8 pitch (CT reconstruction is performed at 5 mm slice). The following are SPECT image parameters: 64 projections, $128 \times 128$ matrix, 20 s/projection, noncircular orbit over 360° (tomographic images are reconstructed using 3-dimensional ordered-subset expectation maximization iterative reconstruction [8 iterations, 4 subsets], and a CT-based attenuation correction algorithm was applied).

**Flood source:** An image obtained with a flood source may be considered to outline body contour.

**24-h neck uptake/residual fraction:** Quantitative measurement of RAIU in the neck is often helpful in determining the mass of remaining thyroid tissue or tumor and is usually acquired at 24 h after administration of $^{123}$I-NaI or $^{131}$I-NaI. The desired value after near-total or total thyroidectomy is 0.5%–5%. The technique is as follows:
1. Uptake is typically measured with 25–30 cm between the face of the crystal and the area(s) of interest.
2. One example among variable techniques using an uptake probe and software is as follows. Acquire counts for 1 min for each of the following: over the thyroid bed, patient’s thigh (body background), room background, and a calibrated standard (radiopharmaceutical source identical to that administered to the patient) contained in a neck phantom.

3. The 24-h RAIU can then be calculated as:
\[
\text{Neck counts} - \text{thigh counts} \times \frac{100}{\text{Phantom count} - \text{background}}
\]

- **18F-FDG PET/CT**: Follow the usual PET/CT oncology protocol. Acquisition should be in the 3D mode.

**F. Interpretation Criteria**

*Physical Examination.* An adequate physical examination and history should be obtained. Palpable soft tissue in the neck should be correlated with scintigraphic findings.

*Thyroid Bed Activity.* Particular attention should be paid to any activity in the thyroid bed. Planar images may not differentiate between thyroid bed residual normal thyroid tissue (i.e., thyroid remnants) versus thyroid malignancy. Lateral and oblique planar views or preferably SPECT/CT may be useful in this case to help separate thyroid bed activity from adjacent lymph node activity.

*Image Correlation.* Findings on physical examination and scintigraphy should be correlated with any additional imaging if available (i.e., CT, MR, ultrasound, other nuclear medicine studies).

**VII. DOCUMENTATION/REPORTING**

For general recommendations on all nuclear medicine reports, see the SNMMI Procedure Standard for General Imaging and the American College of Radiology Practice Guideline for Communication: Diagnostic Radiology.

**A. Indications**

The report should briefly summarize the reason for the examination, pertinent medical or surgical history, and the results of any relevant laboratory tests or prior imaging studies.

**B. Technique**

The report should include the name of the radiopharmaceutical administered, the dosage, and the scanning protocol.

**C. Findings**

The report should include the location and character of any abnormal uptake, comparison with the results of prior imaging studies (if pertinent or available), and any pertinent additional CT findings (if CT was performed with SPECT). If obtained, the quantitative 24-h 123I-Na131I uptake value should also be reported along with a qualitative estimate of the size, activity, and location of any areas of uptake that correspond to any functioning normal or abnormal thyroid tissue.

**D. Impression**

The impression should include conclusions, diagnoses, or differential diagnoses to answer questions posed by the referring clinician or team or to answer any unexpected findings, any recommendations for further work-up.

**VIII. QUALITY CONTROL AND IMPROVEMENT**

See the SNMMI Procedure Standard for General Imaging for general recommendations.

**A. Possible Sources of Error**

- Local contamination (clothing, skin, hair, collimator, imaging table)
- Esophageal activity
- Asymmetric salivary gland uptake
- Breast uptake
- Thymic uptake
- Ectopic thyroid tissue
- Uptake by nonthyroid neoplasms
- Inadequate patient preparation

**IX. SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION CONCERNS**

See the SNMMI Procedure Standard for General Imaging for general recommendations.

**TABLE 3**

Radiation Dosimetry for Adults

<table>
<thead>
<tr>
<th>Radiopharmaceuticals</th>
<th>Administered activity (MBq [mCi])</th>
<th>Organ Receiving largest radiation dose (mGy/MBq [rad/mCi])</th>
<th>Effective dose (mSv/MBq [rem/mCi])</th>
</tr>
</thead>
<tbody>
<tr>
<td>18F-FDG</td>
<td>370–740 intravenously (10–20)</td>
<td>0.15 bladder wall (0.56)</td>
<td>0.019 (0.07)</td>
</tr>
<tr>
<td>Na123I iodide (0% thyroid uptake)</td>
<td>74–148 by mouth (2–4)</td>
<td>0.097 bladder wall (0.36)</td>
<td>0.010 (0.039)</td>
</tr>
<tr>
<td>Na131I iodide (0% thyroid uptake)</td>
<td>37–148 by mouth (1–4)</td>
<td>0.66 bladder wall (2.4)</td>
<td>0.058 (0.21)</td>
</tr>
</tbody>
</table>


X. RADIATION SAFETY IN IMAGING

See the SNMMI Procedure Standard for General Imaging for general recommendations. It is the position of SNMMI that exposure to ionizing radiation should be at the minimum level (ALARA: as low as reasonably achievable) needed to obtain a diagnostic examination. Radiation dosimetry for adults is presented in Table 3.

XI. ACKNOWLEDGMENTS

The Committee on SNMMI Procedure Standards consists of the following individuals: Dominique Delbeke, MD (Chair) (Vanderbilt University Medical Center, Nashville, TN); Helena Balon, MD (Beaumont Health System, Royal Oak, MI); Twyla B. Bartel, DO, MBA (Global Advanced Imaging, PLLC, Little Rock, AR); Pradeep Bhandhavti, MD (The University of Alabama at Birmingham, Birmingham, AL); David Brandon, MD (Emory University/Atlanta VA Medical Center, Atlanta, GA); Vasken Dilisizian, MD (University of Maryland Medical Center, Baltimore, MD); Kevin J. Donohoe, MD (Beth Israel Deaconess Medical Center, Boston, MA); Saeed Elojeimy, MD, PhD (University of New Mexico, Albuquerque, NM); James R. Galt, PhD (Emory University Hospital, Atlanta, GA); Michael L. Goris, MD, PhD (Stanford, CA); Bennett S. Greenspan, MD (UCSF Medical Center, Boston, MA); Twyla B. Bartel, DO, MBA (Global Advanced Imaging, PLLC, Little Rock, AR); Pradeep Bhambhvani, MD (V A Medical Center, Atlanta, GA); J. Anthony Parker, MD, PhD (Emory University Hospital, Atlanta, GA); Kevin J. Donohoe, MD (Beth Israel Deaconess Medical Center, Boston, MA); Heiko Schöder, MD (Memorial Sloan Kettering Cancer Center, New York, NY); Barry Shulkin, MD, MBA (St. Jude Children’s Research Hospital, Memphis, TN); Michael G. Stabin, PhD (Vanderbilt University, Nashville, TN); and Mark Tulchinsky, MD, FACNM, CCE (Penn State Health Milton S. Hershey Medical Center, Hershey, PA).

XII. BIBLIOGRAPHY

7. Chen S, Li N, Li X, et al. 74 MBq 131I for diagnostic scan can decrease the uptake of 131I by thyroid remnants or metastases, the thyroid stunning exists. Q J Nucl Med Mol Imaging. 2015;59:455–461.
25. Liu Y. The role of 18F-PET/CT in the follow-up of well-differentiated thyroid cancer with negative thyroglobulin but positive and/or elevated anti-thyroglobulin antibody. Nucl Med Commun. 2016;37:577–582.
27. McDougall IR. 74 MBq radioiodine does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun. 1997;18:505–512.


XIII. APPROVAL

The Board of Directors of the SNMMI approved version 4.0 at the SNMMI Mid-Winter Meeting in January 2020.
SNMMI Procedure Standard for Scintigraphy for Differentiated Thyroid Cancer

Twyla B. Bartel (Chair), Samuel Magerefteh, Anca M. Avram, Helena R. Balon, Lorraine E. De Blanche, Simin Dadparvar, Mickaila Johnston and Shari Moreau

Doi: 10.2967/jnmt.120.243626

This article and updated information are available at:
http://tech.snmjournals.org/content/48/3/202

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://tech.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNMT can be found at:
http://tech.snmjournals.org/site/subscriptions/online.xhtml